Viridian Therapeutics, Inc.\DEVRDNEarnings & Financial Report
Nasdaq
VRDN Q3 2025 Key Financial Metrics
Revenue
$70.6M
Gross Profit
N/A
Operating Profit
$-40.0M
Net Profit
$-34.6M
Gross Margin
N/A
Operating Margin
-56.7%
Net Margin
-49.0%
YoY Growth
81958.1%
Financial Flow
Viridian Therapeutics, Inc.\DE Q3 2025 Financial Summary
Viridian Therapeutics, Inc.\DE reported revenue of $70.6M for Q3 2025, with a net profit of $-34.6M (-49.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $70.6M |
|---|---|
| Net Profit | $-34.6M |
| Gross Margin | N/A |
| Operating Margin | -56.7% |
| Report Period | Q3 2025 |
Viridian Therapeutics, Inc.\DE Annual Revenue by Year
Viridian Therapeutics, Inc.\DE annual revenue history includes year-by-year totals (for example, 2024 revenue was $302.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $302.0K |
| 2023 | $314.0K |
| 2022 | $1.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72000 | $72000 | $72000 | $86000 | $72000 | $72000 | $75000 | $70.6M |
| YoY Growth | -31.4% | -26.5% | 0.0% | 19.4% | 0.0% | 0.0% | 4.2% | 81958.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $490.4M | $630.4M | $585.7M | $771.9M | $742.4M | $661.0M | $582.3M | $577.1M |
| Liabilities | $48.4M | $47.9M | $56.3M | $64.4M | $70.8M | $56.5M | $67.2M | $74.2M |
| Equity | $442.0M | $582.5M | $529.3M | $707.5M | $671.6M | $604.5M | $515.2M | $503.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-38.0M | $-45.2M | $-46.1M | $-67.7M | $-73.3M | $-92.7M | $-75.4M | $-84.6M |